<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03858062</url>
  </required_header>
  <id_info>
    <org_study_id>NL55693.018.15</org_study_id>
    <nct_id>NCT03858062</nct_id>
  </id_info>
  <brief_title>Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format,</brief_title>
  <acronym>APPEL5</acronym>
  <official_title>Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format, APPEL 5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>J.H. DeVries</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inreda Diabetic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In previous studies, the investigators tested the feasibility of a bi-hormonal reactive
      closed loop system without mealtime announcement. This system for automated control of blood
      glucose in patients with type 1 diabetes was tested in the clinical research center (APPEL 1
      and 2) as well as at the home of the patients (APPEL 3 and 4). After the APPEL 4 study some
      improvements have been made to the miniaturized prototype to allow patients to operate the
      system independently and additional risk control measures were included. The main objective
      of this study is to assess the efficacy of this improved closed loop system.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2019</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in target</measure>
    <time_frame>Week 1-2</time_frame>
    <description>Proportion of time spent in the target range (3.9-10 mmol/l)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in hypoglycemia 1</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Proportion of time spent in hypoglycemia (&lt;3.9 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hypoglycemia 2</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Proportion of time spent in hypoglycemia (&lt;3.3 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hyperglycemia 1</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Proportion of time spent in hyperglycemia (&gt;10 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hyperglycemia 2</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Proportion of time spent in hyperglycemia (&gt;13.9 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Number of carbohydrate-treated hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean or median glucose</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Mean or median sensor glucose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean or median day glucose</measure>
    <time_frame>Day time: Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Mean or median sensor glucose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean or median night glucose</measure>
    <time_frame>Night time: Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Mean or median sensor glucose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean or median postprandial glucose</measure>
    <time_frame>Postprandial: Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Mean or median sensor glucose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability 1</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Interquartile range (IQR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability 2</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Coefficient of variation (CV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability 3</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Low blood glucose index (LBGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability 4</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>High blood glucose index (HBGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability 5</measure>
    <time_frame>Week 1-2 / Week 1 / Week 2</time_frame>
    <description>Blood glucose risk index (BGRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in target</measure>
    <time_frame>Week 1 / Week 2</time_frame>
    <description>Proportion of time spent in the target range (3.9-10 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAID: Problem Areas In Diabetes questionnaire</measure>
    <time_frame>Baseline / End week 2</time_frame>
    <description>Total score; Scale 0 (no problems) to 80 (big problems)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D: EuroQol 5 Dimensions questionnaire</measure>
    <time_frame>Baseline / End week 2</time_frame>
    <description>Quality of life measure; Scale 1 (&quot;no problem) to 5 (&quot;extreme problems&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DTSQ-status: Diabetes Treatment Satisfaction Questionnaire</measure>
    <time_frame>Baseline / End week 2</time_frame>
    <description>Total score: Scale 0 (negative) to 36 (positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DTSQ-change: Diabetes Treatment Satisfaction Questionnaire</measure>
    <time_frame>End week 2</time_frame>
    <description>Change in DTSQ; Total score: Scale -18 (negative) to 18 (positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Algorithm active time</measure>
    <time_frame>Week 1-2 (closed loop only)</time_frame>
    <description>Percentage of time that the closed loop algorithm is active</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability score</measure>
    <time_frame>End week 2 (closed loop only)</time_frame>
    <description>Questionnaire: Mobile Phone Usability Questionnaire (MPUQ); Total score: Scale 62 (low level of usability) to 310 (higher level of usability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose measurement performance</measure>
    <time_frame>Day 3, 4 or 5 of the training period prior to the closed loop</time_frame>
    <description>MARD</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Demographic variables</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c plasma concentration</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Meals</measure>
    <time_frame>Week 1-2</time_frame>
    <description>Carbohydrate intake</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity 1</measure>
    <time_frame>Week 1-2</time_frame>
    <description>Number of exercise moments per intensity category (&quot;light&quot;, &quot;moderate&quot;, &quot;heavy'&quot;
)</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity 2</measure>
    <time_frame>Week 1-2</time_frame>
    <description>Duration of exercise moments per intensity category (&quot;light&quot;, &quot;moderate&quot;, &quot;heavy'&quot;
)</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity 3</measure>
    <time_frame>Week 1-2</time_frame>
    <description>Total number of exercise moments</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity 4</measure>
    <time_frame>Week 1-2</time_frame>
    <description>Total duration of exercise moments</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin dose</measure>
    <time_frame>Week 1-2</time_frame>
    <description>Daily average</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucagon dose</measure>
    <time_frame>Week 1-2</time_frame>
    <description>Daily average</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Open loop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 days patient-managed Insulin pump therapy (with or without glucose sensor) with blinded continuous glucose monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Closed loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-6 training + 14 days automated blood glucose control with the Artificial pancreas (Inreda Diabetic)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin pump therapy (with or without glucose sensor)</intervention_name>
    <description>Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor</description>
    <arm_group_label>Open loop</arm_group_label>
    <other_name>Continuous subcutaneous insulin infusion (CSII)</other_name>
    <other_name>Sensor augmented pump therapy (SAP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artificial pancreas (Inreda Diabetic)</intervention_name>
    <description>Bi-hormonal reactive closed loop system without mealtime announcement</description>
    <arm_group_label>Closed loop</arm_group_label>
    <other_name>Closed loop therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with diabetes mellitus type 1;

          -  Treated with SAP or CSII for a minimum of 6 months;

          -  Willing and able to sign informed consent.

        Exclusion Criteria:

          -  Impaired awareness of hypoglycemia (score â‰¥ 4) according to Gold and/or Clarke
             questionnaire;

          -  BMI &gt; 35 kg/m2;

          -  HbA1c &gt; 97 mmol/mol (=11.0 %);

          -  Use of heparin, coumarin derivatives or oral corticosteroids;

          -  Use of acetaminophen during the open loop or closed loop period, as this may influence
             the sensor glucose measurements;

          -  Limited ability to see, and to hear or feel alarm signals of the closed loop system;

          -  Skin condition prohibiting needle insertion;

          -  Pregnancy and/or breastfeeding;

          -  Living alone during the night during the closed loop period (the patient may ask
             someone to stay over temporarily);

          -  Expected poor connectivity with internet regarding 24/7 tele monitoring;

          -  Any condition that the local investigator feels would have interfere with trial
             participation or the evaluation of the results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J.H. DeVries, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum, Universiteit van Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>van Bon AC, Luijf YM, Koebrugge R, Koops R, Hoekstra JB, DeVries JH. Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther. 2014 Mar;16(3):131-6. doi: 10.1089/dia.2013.0166. Epub 2013 Nov 13.</citation>
    <PMID>24224750</PMID>
  </reference>
  <reference>
    <citation>Blauw H, van Bon AC, Koops R, DeVries JH; , on behalf of the PCDIAB consortium. Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab. 2016 Jul;18(7):671-7. doi: 10.1111/dom.12663. Epub 2016 Apr 25.</citation>
    <PMID>26996542</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>J.H. DeVries</investigator_full_name>
    <investigator_title>Endocrinologist</investigator_title>
  </responsible_party>
  <keyword>Artificial pancreas</keyword>
  <keyword>Glucose control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

